Phase 4CompletedAge-related condition
China Stroke Primary Prevention Trial (CSPPT)
Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd (Industry)
- Enrollment
- 20,702 enrolled
- Conditions
- Primary Hypertension
- Interventions
- Enalapril/folic acid; Enalapril maleate
- Ages
- adults, older adults
- Registry
- NCT00794885
Full record on ClinicalTrials.gov
From the registry
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
Primary outcomes
- First attack of symptomatic stroke ( ischemic or hemorrhagic)
History
Last registry update
Study completion
Primary completion
Registered
Started
Papers citing this trial
- Association Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and Risk of Stroke in Patients With Hypertension: A Cohort Study
Journal of clinical hypertension (Greenwich, Conn.)